Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Source : Mordor Intelligence Product Pipeline: Progress and Updates ■ TAVALISSE PHASE 1 Lower-Risk Myelodysplastic Syndrome Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4) NSCLC Target: AXL receptor tyrosine kinase (AXL) Milademetan' - Daiichi Sankyo CNS Diseases Target: RIPK1 PRE-CLINICAL PRE-CL In 2023, Gavreto generated around $28 million in revenues from the US alone. Its action mechanism inhibits RET kinase activity by binding to it, blocking signaling pathways essential for cancer ce ...